← Leaderboards
Joseph Barbi
Roswell Park Cancer Institute Corp
$1,141,217
Attributed
$3,423,650
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $861.9K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,423,650 · 1
By mechanism
R01$3,423,650 · 1
Top collaborators
- Mary E Reid8 shared
- Saikrishna Yendamuri8 shared
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Mary E Reid$2,296,661
- Saikrishna Yendamuri$2,302,224
- Richard J O'Connor$21,371,886
- Walter J Storkus$19,974,413
- Wei Zheng$71,826,577
Others in their field
Other Emerging Leaders on “Immune”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$181,310,675
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Ted Ross · University Of Georgia$74,507,826
- Yunda Huang · Fred Hutchinson Cancer Center$73,602,469
- Tony Moody · Duke University$66,767,417
Research focus
ImmuneInvestigationDisorder RiskHigh-Risk CancerImmunologic SurveillanceImmunotherapyAbateDisease ProgressionEventHigh RiskClinical TrialsImmunologicsImmunoregulationCancer ModelCancer PreventionCancer RiskCarcinogenesisDiabetes MellitusChemopreventionChemopreventive AgentExperimental StudyFormer SmokerAnti-CancerLink
Grant awards (8)
Metformin for chemoprevention of lung cancer in obese subjects at high risk$583,338
R01 · FY2025 · CA
Metformin for chemoprevention of lung cancer in obese subjects at high risk$628,294
R01 · FY2024 · CA
Metformin for chemoprevention of lung cancer in obese subjects at high risk$66,036
R01 · FY2024 · CA
Metformin for chemoprevention of lung cancer in obese subjects at high risk$794,005
R01 · FY2023 · CA
Metformin for chemoprevention of lung cancer in obese subjects at high risk$67,940
R01 · FY2023 · CA
Metformin for chemoprevention of lung cancer in obese subjects at high risk$584,429
R01 · FY2022 · CA
Metformin for chemoprevention of lung cancer in obese subjects at high risk$69,151
R01 · FY2022 · CA
Metformin for chemoprevention of lung cancer in obese subjects at high risk$630,457
R01 · FY2021 · CA